Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 3
Submit an article Journal homepage
3,315
Views
241
CrossRef citations to date
0
Altmetric
Review

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

Nathalie Garçon GlaxoSmithKline Biologicals, Rixensart, Belgium. [email protected]
,
David W Vaughn GlaxoSmithKline Biologicals, Rixensart, Belgium
&
Arnaud M Didierlaurent GlaxoSmithKline Biologicals, Rixensart, Belgium
Pages 349-366 | Published online: 09 Jan 2014

References

  • Baras B, Stittelaar KJ, Simon JH et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3(1), e1401 (2008).
  • Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 2(3), 370–383 (1980).
  • Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6, 277–296 (1995).
  • Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59TM adjuvant. Vaccine 26(26), 3209–3222 (2008).
  • Pellegrini M, Nicolay U, Lindert K, Groth N, Della CG. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27(49), 6959–6965 (2009).
  • Brigelius-Flohé R, Traber MG. Vitamin E: function and metabolism. FASEB J. 13(10), 1145–1155 (1999).
  • Burton GW, Traber MG, Acuff RV et al. Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E. Am. J. Clin. Nutr. 67(4), 669–684 (1998).
  • Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic. Biol. Med. 43(1), 4–15 (2007).
  • Azzi A, Gysin R, Kempná P et al. Regulation of gene expression by alpha-tocopherol. Biol. Chem. 385(7), 585–591 (2004).
  • Zingg J-M. Modulation of signal transduction by vitamin E. Mol. Aspects Med. 28(5–6), 481–506 (2007).
  • Wu D, Meydani SN. Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention. J. Leukoc. Biol. 84(4), 900–914 (2008).
  • De la Fuente M, Hernanz A, Guayerbas N, Victor VM, Arnalich F. Vitamin E ingestion improves several immune functions in elderly men and women. Free Radic. Res. 42(3), 272–280 (2008).
  • Franchini A, Bertuzzi S, Tosarelli C, Manfreda G. Vitamin E in viral inactivated vaccines. Poult. Sci. 74(4), 666–671 (1995).
  • Afzal M, Tengerdy RP, Ellis RP, Kimberling CV, Morris CJ. Protection of rams against epididymitis by a Brucella ovis-vitamin E adjuvant vaccine. Vet. Immunol. Immunopathol. 7(3–4), 293–304 (1984).
  • Tengerdy RP, Ameghino E, Riemann H. Serological responses of rams to a Brucella ovis-vitamin E adjuvant vaccine. Vaccine 9(4), 273–276 (1991).
  • Tengerdy RP, Lacetera NG. Vitamin E adjuvant formulations in mice. Vaccine 9(3), 204–206 (1991).
  • Do R, Kiss RS, Gaudet D, Engert JC. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. Clin. Genet. 75(1), 19–29 (2009).
  • Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp. Physiol. 93(1), 27–42 (2008).
  • Liu GCK, Ahrens EH Jr, Schreibman PH, Crouse JR. Measurement of squalene in human tissues and plasma: validation and application. J. Lipid Res. 17(1), 38–45 (1976).
  • Nikkari T, Schreibman PH, Ahrens EH Jr. In vivo studies of sterol and squalene secretion by human skin. J. Lipid Res. 15(6), 563–573 (1974).
  • Huang ZR, Lin YK, Fang JY. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. Molecules 14(1), 540–554 (2009).
  • Reddy LH, Couvreur P. Squalene: a natural triterpene for use in disease management and therapy. Adv. Drug Deliv. Rev. 61(15), 1412–1426 (2009).
  • Nema S, Washkuhn RJ, Brendel RJ. Excipients and their use in injectable products. PDA J. Pharm. Sci. Technol. 51(4), 166–171 (1997).
  • Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336(2), 86–91 (1997).
  • Stoute JA, Kester KE, Krzych U et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178(4), 1139–1144 (1998).
  • Sun P, Schwenk R, White K et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-γ. J. Immunol. 171(12), 6961–6967 (2003).
  • McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33(4), 542–554 (2010).
  • Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, Wyatt R. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J. Virol. 80(3), 1414–1426 (2006).
  • The rgp120 HIV Vaccine Study Group. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191(5), 654–665 (2005).
  • Kuehn BM. CDC advisory committee recommends nearly universal influenza vaccination. JAMA 303(12), 1136 (2010).
  • Sander B, Kwong JC, Bauch CT et al. Economic appraisal of Ontario’s Universal Influenza Immunization Program: a cost–utility analysis. PLoS Med. 7(4), e1000256 (2010).
  • Johnson NPAS, Mueller J. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull. Hist. Med. 76(1), 105–115 (2002).
  • Webster RG, Govorkova EA. H5N1 influenza – continuing evolution and spread. N. Engl. J. Med. 355(21), 2174–2177 (2006).
  • Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine 26(Suppl. 4), D41–D44 (2008).
  • Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 103(1–2), 133–138 (2004).
  • Beyer WEP, Palache AM, Baljet M, Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 7(5), 385–394 (1989).
  • Johansson BE, Cox MM. Influenza viral neuraminidase: the forgotten antigen. Expert. Rev. Vaccines 10(12), 1683–1695 (2011).
  • Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172(9), 5598–5605 (2004).
  • Mozdzanowska K, Maiese K, Gerhard W. Th cell-deficient mice control influenza virus infection more effectively than Th- and B cell-deficient mice: evidence for a Th-independent contribution by B cells to virus clearance. J. Immunol. 164(5), 2635–2643 (2000).
  • Swain SL, Agrewala JN, Brown DM et al. CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol. Rev. 211 8–22 (2006).
  • Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res. 162(1–2), 19–30 (2011).
  • Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343–1351 (2006).
  • Bresson J-L, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367(9523), 1657–1664 (2006).
  • Ehrlich HJ, Müller M, Oh HML et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358(24), 2573–2584 (2008).
  • Khurana S, Chearwae W, Castellino F et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2(15), 15ra5 (2010).
  • Langley JM, Frenette L, Ferguson L et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled Phase 1/2 trial in adults. J. Infect. Dis. 201(11), 1644–1653 (2010).
  • Hampson AW. Ferrets and the challenges of H5N1 vaccine formulation. J. Infect. Dis. 194(2), 143–145 (2006).
  • Baras B, Jacob V, Mossman SP, Wettendorf MA. Immunogenicity of adjuvanted split H5N1 pandemic vaccine in mice. Presented at: Options for the Control of Influenza VI. Toronto, Canada, 17–23 June 2007.
  • Baras B, Stittelaar KJ, Simon JH et al. Immunization with low-dose adjuvanted split H5N1 pandemic vaccine protects ferrets against homologous challenge. Presented at: Options for the Control of Influenza VI. Toronto, Canada, 17–23 June 2007.
  • Baras B, Stittelaar KJ, Kuiken T et al. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine 29(11), 2092–2099 (2011).
  • Mallet C, Baras B, Mossman S et al. Intramuscular immunization with low dose adjuvanted detergent-split H5N1 influenza vaccine protects ferrets against intratracheal challenge with wild-type homologous virus. Presented at: The Third European Influenza Conference. Vilamoura, Portugal, 14–17 September 2008.
  • Mallet C, Baras B, Mossman SP et al. Immunization with low-dose adjuvanted split H5N1/Indonesia/5/2005 vaccine protects ferrets against challenge with wild-type heterosubtypic H5N1 A/Hong-Kong/156/1997 virus. Presented at: 11th International Symposium on Respiratory Viral Infections. Bangkok, Thailand, 19–22 February 2009.
  • Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370(9587), 580–589 (2007).
  • Chu DW-S, Hwang S-J, Lim FS et al. Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: a Phase III study in a large population of Asian adults. Vaccine 27(52), 7428–7435 (2009).
  • Langley JM, Risi G, Caldwell M et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a Phase III, placebo-controlled, randomized study. J. Infect. Dis. 203(12), 1729–1738 (2011).
  • Lasko B, Reich D, Madan A, Roman F, Li P, Vaughn D. Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03A-adjuvanted vaccination in adults. J. Infect. Dis. 204(4), 574–581 (2011).
  • Schwarz TF, Horacek T, Knuf M et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27(45), 6284–6290 (2009).
  • Schwarz TF, Horacek T, Knuf M, Damman H-G, Gillard P, Jilg W. Single-dose primary vaccination with AS03A-adjuvanted prepandemic H5N1 influenza vaccine is sufficient to induce strong, rapid and broad immune response to booster vaccination after 12 months. Presented at: 3rd Annual Global Vaccine Congress. Singapore, 4 October 2009.
  • Heijmans S, De Meulemeester M, Reynders P et al. AS03-adjuvanted prepandemic influenza vaccine: high immunogenicity in the Elderly. Presented at: 2nd Vaccine Global Congress. Boston, MA, USA, 7–9 December 2008.
  • Viboud C, Boëlle P-Y, Cauchemez S et al. Risk factors of influenza transmission in households. Br. J. Gen. Pract. 54(506), 684–689 (2004).
  • Díez-Domingo J, Garcés-Sanchez M, Baldó J-M et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years. A Phase II, randomized, open, controlled study. Pediatr. Infect. Dis. J. 29(6), e35–e46 (2010).
  • Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 3(2), e1665 (2008).
  • Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin. Vaccine Immunol. 17(11), 1817–1819 (2010).
  • Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191(8), 1210–1215 (2005).
  • Leroux-Roels I, Roman F, Forgus S et al. Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28(3), 849–857 (2010).
  • Risi G, Frenette L, Langley JM et al. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months. Vaccine 29(37), 6408–6418 (2011).
  • Moris P, van der Most R, Leroux-Roels I et al. H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J. Clin. Immunol. 31(3), 443–454 (2011).
  • Greenberg ME, Lai MH, Hartel GF et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N. Engl. J. Med. 361(25), 2405–2413 (2009).
  • Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster J-M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28(7), 1740–1745 (2010).
  • Baras B, de Waal L, Stittelaar KJ et al. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naive ferrets. Vaccine 29(11), 2120–2126 (2011).
  • Madhun AS, Akselsen PE, Sjursen H et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 29(2), 266–273 (2010).
  • Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03A-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin. Infect. Dis. 51(6), 668–677 (2010).
  • Huijskens E, Rossen J, Mulder P et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. Clin. Vaccine Immunol. 18(9), 1401–1405 (2011).
  • Cox CM, Blanton L, Dhara R, Brammer L, Finelli L. 2009 Pandemic influenza A (H1N1) deaths among children – United States, 2009–2010. Clin. Infect. Dis. 52(Suppl. 1), S69–S74 (2011).
  • Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 375(9720), 1100–1108 (2010).
  • Waddington CS, Walker WT, Oeser C et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 340, c2649 (2010).
  • Carmona A, Omeñaca F, Tejedor JC et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months. Vaccine 28(36), 5837–5844 (2010).
  • Langley JM, Reich D, Aggarwal N et al. Immunogenicity and safety of an A/H1N1v 2009 pandemic influenza vaccine formulated with and without AS03 adjuvant in children aged 6 months to less than 9 years. Presented at: Options for the Control of Influenza VII. Hong-Kong, SAR, China, 3–7 September 2010.
  • Ho J, Moir S, Wang W et al. Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS 25(3), 295–302 (2011).
  • Roman F, Clément F, Dewé W et al. Effect on cellular and humoral immune responses of the AS03 Adjuvant System in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin. Vaccine Immunol. 18(5), 835–843 (2011).
  • Hardelid P, Fleming DM, McMenamin J et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009–2010. Euro. Surveill. 16(2), Article 3 (2011).
  • Örtqvist Å, Berggren I, Insulander M, de Jong B, Svenungsson B. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v in Stockholm County, Sweden. Clin. Infect. Dis. 52(10), 1203–1211 (2011).
  • Pelat C, Falchi A, Carrat F et al. Field effectiveness of pandemic and 2009–2010 seasonal vaccines against 2009–2010 A(H1N1) influenza: estimations from surveillance data in France. PLoS ONE 6(5), e19621 (2011).
  • Puig-Barberà J, Arnedo-Pena A, Pardo-Serrano F et al. Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study. Vaccine 28(47), 7460–7467 (2010).
  • Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Vaccine effectiveness in pandemic influenza – primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol. Assess. 14(34), 313–346 (2010).
  • Skowronski DM, Janjua NZ, De Serres G et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 342, c7297 (2011).
  • Valenciano M, Kissling E, Cohen J-M et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009–2010: results of influenza monitoring vaccine effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 8(1), e1000388 (2011).
  • Wichmann O, Stöcker P, Poggensee G et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009–2010. Euro. Surveill. 15(18), 1 (2010).
  • Hamrin J, Bennet R, Eriksson M, Lind G, Örtqvist E. Effectiveness of a mono-valent adjuvanted vaccine (Pandemrix) for the prevention of hospitalisation for influenza A (H1N1)v infection in children. Acta Paediatr. 99(Suppl. 462), 85, PP091 (2010).
  • Andrews N, Waight P, Yung C-F, Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J. Infect. Dis. 203(1), 32–39 (2011).
  • Van Buynder PG, Dhaliwal JK, Van Buynder JL et al. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respi. Viruses 4(4), 171–178 (2010).
  • Walker WT, Faust SN. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev. Vaccines 9(12), 1385–1398 (2010).
  • Rümke HC, Bayas J-M, de Juanes J-R et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a Phase III safety trial. Vaccine 26(19), 2378–2388 (2008).
  • Ballester A, Garces-Sanchez M, Planelles Cantarino MV et al. Pediatric safety eEvaluation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children Aged 3–9 Years: a Phase II study. Presented at: 48th ICAAC. Washington, DC, USA, 25–28 October 2008.
  • Ikematsu H, Nagai H, Kawashima M et al. Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum. Vaccines 6(11), 888–893 (2010).
  • Nicholson KG, Abrams KR, Batham S et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect. Dis. 11(2), 91–101 (2011).
  • Garcia-Sicilia J, Gillard P, Carmona A et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 29(26), 4353–4361 (2011).
  • Tavares F, Nazareth I, Sawchik Monegal J, Kolte I, Vertraeten T, Bauchau V. Active safety follow up of a cohort of pregnant women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine. Presented at: XIII International Symposium on Respiratory Viral Infections. Rome, Italy, 13–16 March 2011.
  • Dauvilliers Y, Montplaisir J, Cochen V et al. Post-H1N1 narcolepsy-cataplexy. Sleep 33(11), 1428–1430 (2010).
  • Han F, Lin L, Warby SC et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann. Neurol. 70(3), 410–417 (2011).
  • Morel S, Didierlaurent A, Bourguignon P et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29(13), 2461–2473 (2011).
  • Hayden MS, West AP, Ghosh S. NF-κB and the immune response. Oncogene 25(51), 6758–6780 (2006).
  • Morel S, Didierlaurent A, Bourguignon P et al. Link between innate responses and the enhanced adaptive response induced by novel adjuvanted vaccines: insight into AS03’s mode of action. Presented at: 8th International Conference on Innate Immunity. Crete, Greece, 15–20 June 2011.
  • Malherbe L, Mark L, Fazilleau N, McHeyzer-Williams LJ, McHeyzer-Williams MG. Vaccine adjuvants alter TCR-based selection thresholds. Immunity 28(5), 698–709 (2008).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.